The second part of our conversation with Craig Burton, MBA, executive director of the Biosimilars Council, a trade and ...

CEO David Joyner highlighted the company's Q4 adjusted EPS of $1.19 and adjusted operating income of $2.7 billion. He introduced 2025 adjusted EPS guidance of $5.75 to $6.00, emphasizing recovery in ...

A study conducted in the UK and Ireland on patients with psoriasis treated with Samsung Bioepis' adalimumab biosimilar, SB5, showed good long-term tolerance and low treatment discontinuation rates, ...

With approvals in rheumatoid arthritis, psoriasis, and Crohn's disease, Humira holds a wide range of indications, but biosimilar versions of the drug led to price erosion beginning in 2023 and ...

Tocilizumab-anoh is approved for multiple conditions, including rheumatoid arthritis and COVID-19, in intravenous and subcutaneous formulations. Phase 3 study confirmed biosimilarity between ...

Teva Pharmaceutical Industries TEVA reported fourth-quarter 2024 adjusted earnings of 71 cents per share, which beat the Zacks Consensus Estimate of 70 cents. Adjusted earnings declined 29% year over ...

The U.S. Department of Veterans Affairs will replace Humira with the biosimilar Hadlima on its national formulary, according to a press release from Organon, which markets biosimilar. Hadlima ...

SB5, an adalimumab biosimilar approved in the US, is showing to be safe and effective for patients with psoriasis in the long term, according to a study from the UK and Ireland. Patients with ...

AbbVie faces a significant challenge in managing the revenue decline of Humira, its longtime blockbuster drug. As biosimilar competition intensifies, Humira's market share is expected to erode ...

Vizient, Inc. released its new Spend Management Outlook representing the best estimate of the change in the price of pharmaceuticals, medical devices and supplies, capital equipment and services ...